20-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV 20)
Classification:
Products in the Pipeline
- Product Description
- Immunogenicity
- Security
- Mad Dog Bite Cases
-
Manufacturing Process
It covers 20 different serotypes of pathogenic pneumococcal strains commonly found in China with a broader protection range. With safety and environmentally friendly design concepts and advanced technical method, it adopts diphtheria toxin avirulent mutant CRM197 protein as the polysaccharide-binding carrier and perform the glycoprotein binding by amino reduction method with good stability. The vaccine shows excellent stability and immunogenicity in the clinical study, ensuring the better safety and immunogenicity.
Current Progress
Preparation for Investigational New Drug (IND) application.
Previous Page
Other Products
Inactivated Japanese Encephalitis Vaccine for Human Use (Vero cell) (IJEV)
SPEEDA-Rabies Vaccine for Human Use (Vero cell) (CPRV)
Rabies Vaccine (Human Diploid Cell) for Human Use, Freeze-dried (HDCV)
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent (QIV)
13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV 13)
Recombinant Human Papillomavirus 15-valent Vaccine (Escherichia. Coli) (HPV 15)
Follow us
Telephone
Marketing Center
International Trade
Medical Consultation
Address
No.1, XinFang Street, Hunnan New District, Shenyang City
123456789
12456789